Keyword Search
 

2018 | 2017 | 2016 | 2015 | 2014
Ocular Therapeutix™ to Present at the H.C. Wainwright 20th Annual Global Investment Conference

Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update

Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results

Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA®

Ocular Therapeutix™ Announces NDA Resubmission of DEXTENZA™

Ocular Therapeutix™ to Present at the 2018 JMP Securities Life Sciences Conference

Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update

Ocular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix™ to Report First Quarter 2018 Financial Results

Ocular Therapeutix™ to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix™ To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2017 Financial Results and Business Update

Ocular Therapeutix™ to Present at the Cowen and Company 38th Annual Health Care Conference

Ocular Therapeutix™ To Report Fourth Quarter 2017 Financial Results

Ocular Therapeutix™ to Participate in the 2018 Glaucoma 360 Meeting in San Francisco

Ocular TherapeutixTM Announces Closing of Public Offering of Common Stock

Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Ocular Therapeutix™ Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality